Application of serum hepatitis B virus large surface protein determination in lamivudine anti-viral therapy for patients with hepatitis B.
- Author:
Guang-yi LI
1
;
Jiang-li SHENG
;
Hai-jun HUANG
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Antiviral Agents; therapeutic use; DNA, Viral; genetics; Enzyme-Linked Immunosorbent Assay; Female; Hepatitis B; blood; drug therapy; virology; Hepatitis B virus; drug effects; genetics; metabolism; Humans; Lamivudine; therapeutic use; Male; Middle Aged; Polymerase Chain Reaction; methods; Treatment Outcome; Viral Envelope Proteins; blood; Young Adult
- From: Chinese Journal of Experimental and Clinical Virology 2008;22(2):133-135
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the correlation between serum hepatitis B virus large surface protein (HBV-LP) and hepatitis B virus DNA (HBV-DNA) load in hepatitis B patients treated with lamivudine, and the application of serum HBV-LP measurement in evaluation of lamivudine therapeutic effect and end point judgement.
METHODSHBV DNA was detected by fluorescent quantitative PCR (FQ-PCR), serum HBV-LP was detected by enzyme linked immunosorbent assay (ELISA).
RESULTSBoth HBV-DNA and HBV-LP decreased in patients responding to lamivudine therapy, and HBV-LP turned negative 3 months later than HBV-DNA. In patients resistant to lamivudine therapy, neither HBV-DNA nor HBV-LP turned negative. In patients whose symptoms relapsed, HBV-LP didn't turn negative, while HBV-DNA was undetectable only transitorily.
CONCLUSIONMeasuring serum HBV-LP dynamically can be useful in evaluation of lamivudine therapeutic effect.
